Eli Lilly is expected to report earnings per share of $6.26 and revenue of $22.61 billion, according to analyst estimates from LSEG. The company's growth is largely attributed to its successful obesity drug Zepbound and diabetes medication Mounjaro.
Investors are particularly interested in the performance of Foundayo, which was launched in April and is projected to generate approximately $229 million in sales. Despite facing lower net prices in the U.S., Eli Lilly continues to dominate the market, outpacing its main competitor, Novo.
The company is also actively pursuing growth through acquisitions, having recently announced plans to buy a psychedelics drugmaker and three vaccine manufacturers, indicating a strategic shift towards expanding its portfolio in high-growth areas